Prevention of tolerance to stimulant ADHD medication

USPTO granted patent US12594250B2 to James Martin Swanson for methods of preventing accumulated tolerance to stimulant medication used in ADHD treatment. The patent discloses pharmaceutical compositions with controlled-release formulations combining immediate-release and sustained-release components to counteract acute tolerance. The patent contains 16 claims covering methods of treatment using ascending delivery profiles.

Hydroflumethiazide composition for treating TNF-α-related diseases

USPTO granted Patent US12594279B2 to SK Chemicals Co., Ltd. for a composition containing hydroflumethiazide as an active ingredient for preventing or treating TNF-α-related diseases. The patent covers formulations effective at inhibiting TNF-α expression, demonstrating superior efficacy compared to methotrexate and hydroxychloroquine for rheumatoid arthritis treatment. The patent includes 8 claims and covers CPC classifications related to pharmaceutical compositions.

Bexagliflozin extended-release tablet, SGLT2 inhibitor formulation

The USPTO granted patent US12594243B2 to TheracosBio, LLC for an extended-release tablet formulation of the SGLT2 inhibitor bexagliflozin. The patent covers formulations designed to achieve lower peak plasma concentrations (Cmax) compared to immediate-release forms while maintaining therapeutic drug levels over extended periods. The patent contains 7 claims and provides intellectual property protection for the drug delivery technology through 2040.

IL-17 antagonist compositions for treating inflammatory arthritis

USPTO granted patent US12594333B2 to Novartis AG covering methods of treating inflammatory arthritis using IL-17 antagonists, specifically IL-17 binding molecules such as secukinumab antibodies. The patent contains 16 claims and covers therapeutic regimens for conditions including psoriatic arthritis.

Methods of treating psoriasis with secukinumab

The USPTO granted patent US12594332B2 to Novartis AG covering novel regimens for treating psoriasis using secukinumab, an IL-17 antibody antagonist. The patent includes 11 claims directed to therapeutic methods employing the antibody. The patent application was filed on December 16, 2024, with inventors including Achim Guettner, Matthias Machacek, Charis Papavassilis, and Oliver Sander.

LILRB2 Antibodies and Uses Thereof - Cancer and Autoimmune Treatment

The USPTO granted patent US12596122B2 to The Board of Regents of the University of Texas System covering LILRB2 antibodies and their uses for detecting and treating cancer and autoimmune diseases. The patent names 11 inventors and includes 26 claims. The filing date was January 28, 2021, under application number 17759800.

Systems and methods for simulating cardiovascular fluid flow

USPTO granted patent US12594417B2 to Technologies Lifeengine Inc. for a system and methods simulating cardiovascular fluid flow with pulsatile flow and systemic resistance components. The system includes a reservoir, pump, input and output channels with valves, and a processor configured to control valves to generate target fluid flow profiles in test members. The patent contains 18 claims covering both systems and methods for cardiovascular flow simulation.

Surgical instrument ports configured for use with wound retractors

The USPTO granted patent US12594408B2 to Intuitive Surgical Operations, Inc. covering surgical instrument ports designed for use with wound retractors. The patent protects a surgical port featuring a channel through an end face to receive a surgical instrument cannula, with a lateral wall enclosing an open volume. The wound retractor end portion engages the inner surface of the lateral wall, with the port configured to abut a body wall in an inserted position.

Surgical port sleeve with reversible radially expandable flanges - Patent granted

USPTO granted patent US12594409B2 to University Hospitals Cleveland Medical Center for a surgical port retention sleeve with reversible radially expandable flanges. The invention comprises a first sleeve portion, a second sleeve portion, and a reversible locking mechanism where sliding the outer sleeve distally expands collapsible flanges for port fixation. The patent covers 13 claims.

Multi-needle delivery assembly patent granted April 7

USPTO granted patent US12594407B2 to Beijing BOE Technology Development Co., Ltd. for a preparation delivery assembly with multiple needles of varying lengths. The assembly features a first substrate, second substrate, and side walls defining a chamber, with needles arranged on the second substrate surface and in communication with the chamber. The patent contains 15 claims and was filed on June 16, 2022.